Recent CMS guidance on how to answer M2020 (Management of oral medications) and M2030 (Management of injectable medications) represents a shift from previous guidance.
Check out this OASIS Q&A with answers provided by Karen Tibbs, RN, MS, HCS-D, COS-C, quality manager OASIS and coding with McBee Associates.
Agencies should start educating staff now and not wait until the last minute to prepare for the upcoming implementation of OASIS-E on Jan. 1, 2023.
Use these scenarios related to GG0130A (Eating) to quiz your clinicians and ensure accuracy and compliance.
Following a two-year delay in implementation due to the COVID-19 public health emergency (PHE), OASIS-E will be required for assessments beginning Jan. 1, 2023.
To really move the needle on 5-star ratings, leaders should meet with clinicians who are conducting OASIS assessments at key points including start of care, resumption of care, discharge or transfer.
Whether to transfer a patient with a discharge or without discharge has been causing much confusion among agencies in wake of the Patient-Driven Groupings Model (PDGM) implementation on Jan. 1.
Reeducate clinicians on the definition of “clinically significant” to help improve accuracy and potentially save time when responding to M2001 (Drug regimen review) and M2003 (Medication follow-up).
When responding to pressure ulcer items on the OASIS, clinicians can collaborate when only a partial skin assessment is completed on the first visit, according to the most recent release of CMS quarterly OASIS Q&As.
Following a recent DecisionHealth webinar about addressing the key challenges clinicians face with OASIS-D, agencies asked questions of industry expert Karen Tibbs, quality and education manager with Wayne, Pa.-based McBee Associates.


User Name: